ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
64 357,06
0,73%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. PhaseBio Pharmaceuticals Inc (PHAS)

  7. PhaseBio Pharmaceuticals Inc (PHAS) Actualités

PHAS

PhaseBio Pharmaceuticals (PHAS)

PhaseBio Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PHAS
DateHeureSourceTitreSymboleSociété
30/05/202322h03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
19/05/202322h19Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
16/05/202322h23Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
03/04/202322h06Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
14/02/202323h07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
21/12/202212h10Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
04/11/202221h44Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
24/10/202214h00Business WirePhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy CodeNASDAQ:PHASPhaseBio Pharmaceuticals Inc
28/09/202218h05TipRanksPhasebio Pharmaceuticals (PHAS) was downgraded to a Hold Rating at NeedhamNASDAQ:PHASPhaseBio Pharmaceuticals Inc
15/08/202212h15TipRanksH.C. Wainwright Keeps Their Buy Rating on Phasebio Pharmaceuticals (PHAS)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
12/08/202222h15TipRanksPhasebio Pharmaceuticals (PHAS) Receives a Buy from NeedhamNASDAQ:PHASPhaseBio Pharmaceuticals Inc
12/08/202214h30Business WirePhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business HighlightsNASDAQ:PHASPhaseBio Pharmaceuticals Inc
16/06/202214h18TipRanks10 Penny Stocks that Could Deliver Exponential ReturnsNASDAQ:PHASPhaseBio Pharmaceuticals Inc
17/05/202212h26TipRanksH.C. Wainwright Thinks Phasebio Pharmaceuticals’ Stock is Going to RecoverNASDAQ:PHASPhaseBio Pharmaceuticals Inc
16/05/202217h55TipRanksAnalysts Offer Insights on Healthcare Companies: Phasebio Pharmaceuticals (PHAS) and Hookipa Pharma (HOOK)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
16/05/202212h51Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
16/05/202212h00Business WirePhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for BentracimabNASDAQ:PHASPhaseBio Pharmaceuticals Inc
16/05/202212h00Business WirePhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business HighlightsNASDAQ:PHASPhaseBio Pharmaceuticals Inc
22/04/202222h15Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
18/04/202211h35TipRanksAnalysts Offer Insights on Healthcare Companies: Phasebio Pharmaceuticals (PHAS) and InMode (INMD)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
07/04/202222h00Business WirePhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare ConferenceNASDAQ:PHASPhaseBio Pharmaceuticals Inc
04/04/202214h00Business WirePhaseBio Announces Positive Results from Phase 2b Trial for BentracimabNASDAQ:PHASPhaseBio Pharmaceuticals Inc
25/03/202220h15TipRanksNeedham Thinks Phasebio Pharmaceuticals’ Stock is Going to RecoverNASDAQ:PHASPhaseBio Pharmaceuticals Inc
25/03/202211h25TipRanksH.C. Wainwright Reiterates Their Buy Rating on Phasebio Pharmaceuticals (PHAS)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
24/03/202221h16Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PHASPhaseBio Pharmaceuticals Inc
24/03/202221h00Business WirePhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business HighlightsNASDAQ:PHASPhaseBio Pharmaceuticals Inc
08/03/202214h00Business WirePhaseBio Pharmaceuticals Announces Bentracimab Manufacturing UpdateNASDAQ:PHASPhaseBio Pharmaceuticals Inc
24/02/202222h00Business WirePhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care ConferenceNASDAQ:PHASPhaseBio Pharmaceuticals Inc
10/02/202214h00Business WirePhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific SessionNASDAQ:PHASPhaseBio Pharmaceuticals Inc
04/02/202215h31Edgar (US Regulatory)Schedule 13gNASDAQ:PHASPhaseBio Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PHAS

Dernières Valeurs Consultées

NYSE
DIS
Walt Disney
EU
ACA
Credit Agricole
EU
SGO
Cie de SaintGobain
EU
VK
Vallourec
NYSE
MRK
Merck
NASDAQ
MSFT
Microsoft
NASDAQ
NVDA
NVIDIA
NASDAQ
AAPL
Apple
EU
DG
Vinci
NYSE
KO
Coca Cola
EU
PX4
SBF 120
EU
VIV
Vivendi
FTSE
UKX
FTSE 100
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés